Prokidney announces online publication of trial design for phase ii multicenter clinical trial of react® autologous cell therapy for treatment of chronic kidney disease

Winston salem, n.c., jan. 27, 2022 (globe newswire) -- prokidney lp (“prokidney”), a leading clinical-stage cellular therapeutics company focused on chronic kidney disease (“ckd”), today announced the publication of the trial design of its phase ii clinical study of its novel renal autologous cell therapy (react®) in the american journal of nephrology. the paper, titled novel renal autologous cell therapy for type 2 diabetes mellitus chronic diabetic kidney disease: clinical trial design, was published online and will appear in a future print edition of the journal (doi: 10.1159/000520231).
PROK Ratings Summary
PROK Quant Ranking